Skip to content

The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Clinical trials

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer

Recruiting nowPhase 3Randomised

What this trial is trying to do

The researchers think that sparing the tumour-draining lymph nodes during short-course radiotherapy may preserve immune activation, while radiation, chemotherapy and a PD-1 inhibitor—an immunotherapy that helps immune cells attack cancer—work together against mid- or low-rectal cancer. The trial is testing this sequence against conventional radiotherapy followed by chemotherapy, with the idea that it could make MSS/pMMR cancers more responsive to PD-1 blockade.

The comparison asks whether node-sparing treatment increases the rate of complete responses, and later whether it improves the time before the cancer returns or progresses, sphincter preservation, treatment tolerance and prognosis. Preserving the sphincter could help some patients avoid permanent colostomy, but the main reported outcome here is complete response rather than longer survival.

Worth knowing: The trial is limited to mid- or low-rectal cancers that are pMMR/MSS, and complete response is not the same as proven longer survival.

Written from the trial's own registry entry to explain what the researchers are testing and why. Nothing here is a result — this trial has not reported one — and it is not a view on whether the treatment works or on whether it would suit you.

The trial at a glance
Registry number NCT06958432
Recruitment Recruiting now
Phase Phase 3
Design randomised, open label
Taking part 430 people (planned)
Who can join aged 18 Years to 75 Years
Run by Sixth Affiliated Hospital, Sun Yat-sen University
Started
Main results expected
Record last updated

What is being tested

  • Combination product Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor
  • Combination product Conventional Radiotherapy plus Chemotherapy

What it is measuring

Complete response (CR) rate

This is the trial's main question — the one it is designed and sized to answer. Anything else it reports is a secondary finding, and secondary findings are far more likely to be chance.

Phase 3. Compares the treatment against current standard care in a large group. This is the design that changes practice.

How the researchers describe it

Most rectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR) and respond poorly to PD-1 inhibitors. Radiotherapy can enhance tumor antigen release and improve responsiveness to PD-1 blockade in MSS/pMMR rectal cancer. Tumor-draining lymph nodes (TDLNs) are critical sites for anti-tumor immune activation, but radiation-induced damage and fibrosis may impair lymphatic drainage and immune responses. Previous studies have reported a remarkable pathologic complete response (pCR) rate of 77.8% using node-sparing radiotherapy in locally advanced rectal cancer. This study aims to evaluate whether node-sparing short-course radiotherapy followed by sequential chemotherapy and PD-1 blockade can improve complete response rate in the phase II part and event-free survival in phase III part, together with sphincter preservation, treatment tolerance, and prognosis in patients with mid-low pMMR/MSS rectal cancer.

Written by the trial’s sponsor, quoted from its ClinicalTrials.gov record.

What this trial is looking for

Genotype

  • Any genotype

Read automatically from the criteria below, to make the list searchable. It is a summary of what the text mentions, not a decision about whether you qualify — and where the two disagree, the criteria are right and this is wrong.

Who the trial is looking for

Inclusion Criteria

  • • Voluntarily signs a written informed consent form.
  • Aged between 18 and 75 years at the time of enrollment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Expected survival of more than 2 years.
  • Histologically confirmed rectal adenocarcinoma.
  • Tumor biopsy indicates proficient mismatch repair (pMMR), defined by positive immunohistochemical staining for MLH1, MSH2, MSH6, and PMS2, or molecular testing confirms microsatellite stability (MSS).
  • Clinical stage T3-4N0M0 or TanyN+M0 based on the 8th edition of the AJCC TNM classification, as evaluated by high-resolution MRI ± endoscopic ultrasound/transrectal ultrasonography, with the tumor located in the mid-to-lower rectum below the peritoneal reflection.
  • Prior to enrollment, a qualified surgical attending physician must assess the patient's medical history and confirm eligibility for curative R0 resection.
  • No prior systemic or local anti-tumor treatment for rectal cancer, including radiotherapy, chemotherapy, immunotherapy, biologics, or small-molecule targeted therapy.
  • Adequate organ function, defined as follows:
  • Hematologic (without use of blood components or growth factors within 7 days prior to treatment initiation):
  • Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L
  • Platelet count ≥ 100 × 10⁹/L
  • Hemoglobin ≥ 90 g/L
  • Renal:
  • Cal…

This is an extract. Whether you qualify is decided by the trial team against the full criteria, not by reading this page. Read the full eligibility criteria

Where it is running

Running at 1 site. Listed in: China.

Individual hospitals, and whether each is currently open, are listed on the registry record. Sites open and close throughout a trial.

Worth asking your oncology team

Being listed here is not a recommendation, and no one page can tell you whether a trial is right for you. These are the questions it raises.

  • Is this trial open at a hospital I could realistically travel to?
  • Given my stage, my previous treatment and my tumour's molecular profile, would I be eligible?
  • What would I be giving up by joining — is the comparison arm the treatment I would otherwise be having?
  • What is already known about the safety of what is being tested?

The source

Registry record NCT06958432, registered by Sixth Affiliated Hospital, Sun Yat-sen University on ClinicalTrials.gov, a public database run by the US National Library of Medicine. The details on this page come from that record and are only ever as current as the sponsor has kept it.

This is a listing of a registered clinical trial, reproduced for information. It is not a recommendation, this site has no connection to the trial or its sponsor, and being listed here says nothing about whether the treatment works. Talk to your own oncology team before pursuing any trial.

This article summarises published research for general information. It is not medical advice, and it is not a substitute for a conversation with your own oncology team, who know your case. Do not start, stop, or change any treatment or supplement on the basis of what you read here.


Other trials being tracked

467 trials

See all trials